T. Rowe Price Investment Management
CLDX icon

T. Rowe Price Investment Management’s Celldex Therapeutics CLDX Stock Holding History

T. Rowe Price Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,697,498
Closed -$42.9M – 662
2024
Q4 		$42.9M Sell
1,697,498
-37,024
-2% -$1.01M 0.03% 429
2024
Q3 		$59M Buy
+1,734,522
New +$66.1M 0.04% 378

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management's CLDX Position: Q1 2025 in Review

T. Rowe Price Investment Management sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 1,697,498 shares — an estimated $42.9M sold.

T. Rowe Price Investment Management first reported a position in CLDX in Q3 2024 and held it in 2 quarters. The position peaked at $59M in Q3 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • T. Rowe Price Investment Management reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,697,498 Celldex Therapeutics shares in Q1 2025, an estimated $42.9M.
  • T. Rowe Price Investment Management first reported a position in Celldex Therapeutics in Q3 2024 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Celldex Therapeutics position peaked at $59M in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2025, filed 14 May 2025.